For event organisers
Everything needed to announce a talk: bios in English and German, a portrait and a stage photo, talk topics and recent conference contributions.
Portrait 1122 × 1402 px · Stage photo 1136 × 1385 px · WebP
Bios
Reinhold Schilling is Head of Global Pharmacovigilance at an internationally operating pharmaceutical group, EU Qualified Person for Pharmacovigilance (EU QPPV) and Stufenplanbeauftragter. He has worked in pharmacovigilance and regulatory affairs since 2011, teaches pharmacovigilance at Goethe Business School and Reutlingen University, and speaks on pharmacovigilance governance and the responsible use of artificial intelligence.
Reinhold Schilling is Head of Global Pharmacovigilance at an internationally operating pharmaceutical group, where he serves as EU Qualified Person for Pharmacovigilance (EU QPPV) and Stufenplanbeauftragter. He holds a Diplom in Chemistry from the University of Bonn and a Master of Drug Regulatory Affairs, and has worked in pharmacovigilance and regulatory affairs since 2011. He teaches pharmacovigilance at Goethe Business School and Reutlingen University and is a member of the Pharmacovigilance Committee of BPI e.V. His conference contributions focus on pharmacovigilance governance and on human-in-the-loop use of artificial intelligence in case processing. He is the author of Practical Pharmacovigilance: From Case Intake to Benefit–Risk Judgement and Die Pharmaindustrie: Rollen, Übergaben und Entscheidungen verstehen, and of the Schilling Vigilance white paper series. He speaks in English and German.
Reinhold Schilling ist Head of Global Pharmacovigilance in einer international tätigen Pharmagruppe, EU Qualified Person for Pharmacovigilance (EU QPPV) und Stufenplanbeauftragter. Er arbeitet seit 2011 in Pharmakovigilanz und Regulatory Affairs, lehrt Pharmakovigilanz an der Goethe Business School und der Hochschule Reutlingen und spricht über Governance in der Pharmakovigilanz und den verantwortungsvollen Einsatz künstlicher Intelligenz.
Talk topics
01
Build a shared understanding of the systems, roles and evidence that support accountable oversight.
02
Connect regulatory expectations with the scientific reasoning behind safety decisions.
03
Examine how robust operations, interfaces and evidence sustain inspection-ready systems.
04
Explore accountable leadership and technology use where judgement remains essential.
Track record
18 September 2026
17th International SLS Days
GxP / AI Governance: From interesting tools to controlled processes
Hannover, Germany
29 April 2026
5th Pharmacovigilance & Drug Safety Conference
Human-in-the-Loop AI for Pharmacovigilance Case Intake: From Raw Emails to Validated E2B(R3) with Measurable QC Time Savings
Madrid, Spain
24 February 2026
European Drug Safety & AI 2026
Human-in-the-Loop AI for Pharmacovigilance Case Intake: From Raw Emails to Validated E2B(R3) with Measurable QC Time Savings
Barcelona, Spain
November 2025
World Drug Safety Congress Americas
AI in Case Management: Limits and Opportunities
Boston, Massachusetts, USA
7–8 October 2025
World Drug Safety Congress Europe
AI in Case Management: Limits and Opportunities
Amsterdam, Netherlands
2025
Chem-Academy Conference
How a Small Company Revolutionized Its Case Intake with theralyze.ai: AI-Powered E2B(R3) Generation for Safety Databases with Human QC, Saving Time and Reducing Manual Effort
Share the audience, topic, date and format, and Reinhold will reply by email.
